ERBB2 and neoplasm: Trastuzumab can also suppress angiogenesis, and trastuzumab-coated HER2-positive tumor cells can undergo antibody-dependent cellular cytotoxicity-mediated lysis upon immune cell recognition (Nahta 2012).